Abstract 1647P
Background
Pancreatic cancer is a highly fatal and aggressive disease due to its discouraging mortality and clinical treatment efficacy. Pancreas is composed of endocrine and exocrine parts, and the interlacing structure of them reminds us of the potential interaction between endocrine and exocrine cells in the oncogenesis and development of pancreatic cancer.
Methods
We depicted the changes of pancreatic endocrine cells in pancreatic cancer tissues by single-cell transcriptome sequencing, spatial transcriptome sequencing and multiplexed immunohistochemistry in human as well as in mouse models. After that, the interaction and sequence between pancreatic cancer oncogenesis and endocrine changes was explored in orthotopic transplantation mice and KPC mice. Finally, we proved the mechanism of the interaction between endocrine and exocrine parts of the pancreas through islet isolation, co-culture in vitro and co-injection in vivo.
Results
We found that, compared with normal pancreatic tissue, pancreatic endocrine cells displayed significantly different transcriptomic characteristics and increased interaction with exocrine part in pancreatic cancer tissues. Specifically, pancreatic polypeptide positive (PP+) cells showed a sharp increment accompanied with the progression of the cancer lesion. From an evolutionary perspective, the increased PP+ cells might be derived from the trans differentiation of α and β cells. Interestingly, in vivo and in vitro experiments proved that pancreatic cancer cells were able to induce the trans differentiation of α cells and β cells into GCG+PP+ and INS+PP+ double-positive cells, which further promoted pancreatic cancer proliferation in a paracrine-dependent manner and formed a positive feedback loop.
Conclusions
Our study systematically mapped the changes of pancreatic endocrine cells in pancreatic cancer and elucidated their relationship with pancreatic cancer oncogenesis and development. Meanwhile, we first time defined and characterized cancer-associated endocrine cells (CAE), which indicated that pancreatic endocrine cells should be an important component of pancreatic cancer microenvironment, thereby providing novel ideas for early diagnosis and targeted therapy of pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Nature Science Foundation of China, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, China Postdoctoral Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1589P - Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin
Presenter: Niels Guchelaar
Session: Poster session 22
1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Presenter: Berenice Freile
Session: Poster session 22
1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Presenter: Tamar Esakia
Session: Poster session 22
1617P - PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Poster session 22
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Alison Schram
Session: Poster session 22
1620P - A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Presenter: Davide Melisi
Session: Poster session 22
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Presenter: Shubham Pant
Session: Poster session 22
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Presenter: Shunsuke Kondo
Session: Poster session 22
1623P - Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Presenter: Dirk Arnold
Session: Poster session 22